Radiation plus hormone therapy may slow resistant prostate cancer
NCT ID NCT07717268
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether adding precise, high-dose radiation (SBRT) to standard second-generation antiandrogen drugs (enzalutamide or abiraterone) can better control prostate cancer that has spread to a few spots and stopped responding to hormone therapy. About 51 men with oligometastatic castration-resistant prostate cancer will receive the combination. Researchers will measure how long it takes for the cancer to progress, overall survival, quality of life, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of stereotactic body radiation therapy (SBRT) and a second-generation antiandrogen (either enzalutamide or abiraterone acetate)
- What this could lead to
- If successful, this combination could delay cancer progression and improve survival and quality of life for men with oligometastatic castration-resistant prostate cancer.
- What could go wrong
- This is a small, single-group Phase 2 trial, so results may not be definitive. The added radiation could increase side effects, and the benefit over antiandrogen alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complexo Hospitalario Universitario De Santiago
ACTIVE_NOT_RECRUITINGSantiago de Compostela, Galicia, 15706, Spain
-
Consorci Sanitari De Terrassa
ACTIVE_NOT_RECRUITINGTerrassa, Catalonia, 08227, Spain
-
Hospital Clinic de Barcelona
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
-
Hospital Clínico San Carlos
RECRUITINGMadrid, Madrid, 28040, Spain
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clínico Universitario De Valladolid
RECRUITINGValladolid, Castille and León, 47003, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital De La Santa Creu I Sant Pau
RECRUITINGBarcelona, Catalonia, 08041, Spain
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Ramón y Cajal
ACTIVE_NOT_RECRUITINGMadrid, Madrid, 28034, Spain
-
Hospital Universitario Basurto
ACTIVE_NOT_RECRUITINGBilbao, Basque Country, 48013, Spain
-
Hospital Universitario Central De Asturias
ACTIVE_NOT_RECRUITINGOviedo, Principality of Asturias, 33011, Spain
-
Hospital Universitario De Salamanca
ACTIVE_NOT_RECRUITINGSalamanca, Castille and León, 37007, Spain
-
Hospital Universitario Miguel Servet
ACTIVE_NOT_RECRUITINGZaragoza, Aragon, 50009, Spain
-
Hospital Universitario de Navarra (HUN)
RECRUITINGPamplona, Navarre, 31008, Spain
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Hospital Universitario y Politécnico de La Fe
ACTIVE_NOT_RECRUITINGValencia, Valencia, 46026, Spain
-
Hospital de Cruces
ACTIVE_NOT_RECRUITINGBarakaldo, Vizcaya, 48903, Spain
-
Instituto Catalán de Oncología Hospitalet
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- Can a Two-Drug attack stall resistant prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- Can a new daily pill slow advanced prostate cancer?
- Targeted radiation zaps prostate cancer cells in new trial
- Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival